Aptamer-target interaction descriptor
Aptamer-target interaction information
Interaction ID: 542
Aptamer sequence: GTATTGCGGAGGAAGGTTTTTAACCTTCGGGG
Target unique ID: 60961
Aptamer ID Aptamer descriptor Target chemistry Target name Affinity Binding Conditions/Buffer PubMed ID
Apta_519 A10-excised Apt Molecule Adenosine 14.8 μM 300 mM NaCl, 5 mM MgC12, 20 mM Tris (pH 7.6) 34084332
Structure information of aptamer
Aptamer Sequence: GTATTGCGGAGGAAGGTTTTTAACCTTCGGGG
The optimal secondary structure in dot-bracket notation: ...........(((((((...)))))))....
The centroid secondary structure in dot-bracket notation: ...........((((((.....))))))....
The MFE structure
The Centroid structure
The mountain plot representation
Aptamer information
Type Detail Type Detail
Aptamer ID Apta_519 Description A10-excised Apt
Aptamer chemistry DNA Length 32 nt
GC content 50.0% Molecular weight 9,966.41 Da
Molarity of 1 μg/μl solution 100.34 μM Number of G-quadruplexes No QGRS found
G-Score N/A Function Aptasensor
Sequence GTATTGCGGAGGAAGGTTTTTAACCTTCGGGG
Applications Specifific recognition of adenosine
Target information
Type Detail Type Detail
PubChem ID 60961 Molecular name Adenosine
Molecular formula C10H13N5O4 Molecular weight 267.24
IUPAC name (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol InChIKey OIRDTQYFTABQOQ-KQYNXXCUSA-N
LogP -1.98 Topological polar surface area 139.54
Hydrogen bond acceptor 9 Hydrogen bond donor 4

Synonym(s):
adenosine; 58-61-7; Adenocard; Adenoscan; Adenine riboside; beta-D-Adenosine; Nucleocardyl; Adenosin; Boniton; Sandesin; Myocol; Adenine nucleoside; Adenocor; beta-Adenosine; 9-beta-D-Ribofuranosyladenine; 9-beta-D-Ribofuranosidoadenine; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; Adenosin [German]; USAF CB-10; 9beta-D-Ribofuranosyladenine; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; Ade-Rib; Caswell No. 010B; Adenosine [USAN:BAN]; (2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; beta-D-Ribofuranoside, adenine-9; 6-Amino-9beta-D-ribofuranosyl-9H-purine; SR 96225; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; Quinquefolan B; D-Adenosine; 3H-adenosine; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; NSC 7652; Dehydran 240; UNII-K72T3FS567; Adenosine (Adenocard); CHEBI:16335; AI3-52413; 9H-Purin-6-amine, 9beta-D-ribofuranosyl-; MFCD00005752; CHEMBL477; SR-96225; beta-D-Ribofuranose, 1-(6-amino-9H-purin-9-yl)-1-deoxy-; adenine-D-ribose; K72T3FS567; CCRIS 2557; 5536-17-4; Adenine-9-beta-D-ribofuranoside; NCGC00023673-05; Pallacor; DSSTox_CID_2558; DSSTox_RID_76628; DSSTox_GSID_22558; 109767-06-8; 133248-01-8; Adenine 9-beta-D-arabinofuranoside; .beta.-D-Adenosine; CAS-58-61-7; Adenocard (TN); Adenoscan (TN); SMR000058216; MEDR-640; Adenosine (JAN/USP); SR-05000001981; EINECS 200-389-9; Adenine-beta-D-arabinofuranoside; NSC 627048; 9-.beta.-d-Ribofuranosyladenine; NSC7652; Adenogesic; Adenosine [USAN:USP:BAN]; Adenin riboside; NSC-7652; .beta.-D-Ribofuranoside, adenine-9; 9-.alpha.-D-Arabinofuranosyladenine; MFCD00065471; NSC627048; b-D-Adenosine; HSDB 7774; SUN-Y4001; N6-Methylado; 1dgm; 1odi; 2fqy; 2ydo; 3axz; 4cki; 4ckj; Adenosine,(S); adenosine-N-15N; adenosine-8-13C; adenosine-9-15N; beta-delta-Adenosine; [U-14C]adenosine; 6-Amino-9.beta.-D-ribofuranosyl-9H-purine; 41547-82-4; 2gl0; 3ay0; 4pd9; Adenosine, >=99%; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; Spectrum2_001257; Spectrum3_000288; cid_191; SCHEMBL731; bmse000061; bmse000996; Epitope ID:140947; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; 9-ss-D-Ribofuranosyladenine; BSPBio_001796; .beta.-D-Ribofuranose, 1-(6-amino-9H-purin-9-yl)-1-deoxy-; cid_60961; MLS000069638; MLS002153227; MLS006010946; SPECTRUM1500107; Adenine-9-ss-D-ribofuranoside; REGID_for_CID_60961; SPBio_001194; adenine-9beta-D-Ribofuranoside; GTPL2844; 9beta-delta-Ribofuranosyladenine; DTXSID1022558; BDBM14487; KBio3_001296; 9-beta-delta-Ribofuranosyladenine; EA6C60C2-6AFB-4264-A2F0-541373DB950E; 9-.beta.-D-Ribofuranosidoadenine; 9-beta-delta-Ribofuranosidoadenine; adenine-9beta-delta-Ribofuranoside; Bio1_000437; Bio1_000926; Bio1_001415; HMS1920A13; HMS2091G13; HMS2235E24; HMS3884O04; Pharmakon1600-01500107; ACT02616; ALBB-032827; AMY30083; XYA; ZINC2169830; 9-beta-delta-Arabinofuranosyladenine; Tox21_110891; AC7861; adenosine-2-13C-N,1,3-15N3; CCG-38824; NSC755857; s1647; AKOS015888594; Tox21_110891_1; AC-8229; AM83931; DB00640; MCULE-7071766082; NSC-755857; SDCCGMLS-0003108.P003; 9-?-D-Ribofuranosyl-9H-purin-6-amine; 9beta-D-ribofuranosyl-9H-Purin-6-amine; NCGC00023673-03; NCGC00023673-04; NCGC00023673-06; NCGC00023673-07; NCGC00023673-10; NCGC00023673-20; NCGC00178869-03; 9-? -D-Ribofuranosyl-9H-purin-6-amine; AC-27494; AS-12664; AT-11502; Adenosine, Vetec(TM) reagent grade, 98%; SBI-0206673.P002; 9beta-delta-ribofuranosyl-9H-Purin-6-amine; AB0012292; DB-022408; 6-Amino-9beta-delta-ribofuranosyl-9H-purine; 9-.beta.-D-Ribofuranosyl-9H-purin-6-amine; 9-beta-delta-Ribofuranosyl-9H-purin-6-amine; A0152; 9H-Purin-6-amine, 9-.beta.-d-ribofuranosyl-; C00212; D00045; AB00384349-11; AB00384349_13; AB00384349_14; Adenosine, BioReagent, suitable for cell culture; Q190012; UNII-F2 component OIRDTQYFTABQOQ-KQYNXXCUSA-N; SR-05000001981-1; SR-05000001981-2; Z1741978458; 1-(6-amino-9H-purin-9-yl)-1-deoxy-beta-D-Ribofuranose; Adenosine, European Pharmacopoeia (EP) Reference Standard; Formycin A, from Streptomyces kaniharaensis, >=98% (HPLC); 1-(6-amino-9H-purin-9-yl)-1-deoxy-beta-delta-Ribofuranose; Adenosine, United States Pharmacopeia (USP) Reference Standard; Adenosine, Pharmaceutical Secondary Standard; Certified Reference Material; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; 142796-17-6; 158749-77-0; 177030-94-3; 244769-76-4

Activity data
Interaction ID 542
Target type Molecule
Target unique ID 60961
Activity 14.8 μM
Binding Conditions/Buffer

300 mM NaCl, 5 mM MgC12, 20 mM Tris (pH 7.6)

Assay

ITC traces and integrated heat for 20 mM one-site aptamer titrated

PubMed ID 34084332
Similar aptamers
Aptamer ID Aptamer chemistry Sequence Similarity
Apta_518 DNA GTATTGCGGAGGAAGGTTTTTAACCTTCGGGGA
96.97%
Apta_678 DNA CGTACGGTGGGAACGGTTCCTCTTAGGGT 56.25%
Apta_267 DNA GAGTGCGTAATGGTACGATTTGGGAAGTGGCTTGGGGTGG 55.00%
Apta_813 DNA TAGAGATATGACAGCGGGGAAGGTTAAGAGGCGCTAGGAG 55.00%
Apta_1270 DNA GTATATCAAGCATCGCGTGTTTACACATGCGAGAGGTGAA 55.00%
Apta_781 DNA GTACGCCGCAAGACGAGTTGTGTATAAGCCGGC 54.55%
Apta_407 DNA GTGAATTGCGTTGAATTATGTTTTTTCAGTCATCACT 54.05%
Apta_50 DNA AGTGGCGAGGGGGGTAGGTAAAGTATCCTTAGTGTGTTG 53.85%
Apta_150 DNA CCGTAGGTTCGGGGCGGAGTGGTCCGGAAGGTGGCGTGG 53.85%
Apta_745 DNA GGTTGCATGCCGTGGGGAGGGGGGTGGGTTTTATAGCGTACTCAG 53.33%
Apta_677 DNA CCAAATGCGACGGGGCCTGTTTTAATGGGG 53.12%
Apta_806 DNA GGTTGGATGTAAGGTTGGAGGGGGG 53.12%
Apta_1195 DNA GGGGTTGGGGGGAGGCGGGGAATGGGGG 53.12%
Apta_1237 DNA GGGGTTGTGTGGGGAGTTTGTCCTGTTGTG 53.12%
Apta_1239 DNA GGTGGATGGGGATGCTTTGTTAGTTTGTGC 53.12%
Apta_148 DNA CCGTAGGTTCGGGGTCGGAGTGGTCCGGAAGGTGGCGTGG 52.50%
Apta_149 DNA CCGTAGGTTCGGGGTCGGAGTGGTCCGGAAGATGGCGTGG 52.50%
Apta_264 DNA GGCGTTGTCGGGCGCAGGTGTAGGCCTCGTGGTGGTGGGT 52.50%
Apta_928 DNA GATTGAGTAGATAGTGGTTCTGTACGTAGTGAAAGAGTGG 52.50%
Apta_498 DNA GAACTCATTGGCTGGAGGCGGCAGTACCGCTTGAGTT 51.35%